Metallo-Drugs in Cancer Therapy: Past, Present and Future.

Autor: Lucaciu RL; Department of Pharmaceutical Biochemistry and Clinical Laboratory, Faculty of Pharmacy, 'Iuliu-Hațieganu' University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania., Hangan AC; Department of Inorganic Chemistry, Faculty of Pharmacy, 'Iuliu-Hațieganu' University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania., Sevastre B; Clinic Department, Faculty of Veterinary Madicine, University of Agricultural Science and Veterinary Medicine, 400372 Cluj-Napoca, Romania., Oprean LS; Department of Inorganic Chemistry, Faculty of Pharmacy, 'Iuliu-Hațieganu' University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Jazyk: angličtina
Zdroj: Molecules (Basel, Switzerland) [Molecules] 2022 Oct 01; Vol. 27 (19). Date of Electronic Publication: 2022 Oct 01.
DOI: 10.3390/molecules27196485
Abstrakt: Cancer treatments which include conventional chemotherapy have not proven very successful in curing human malignancies. The failures of these treatment modalities include inherent resistance, systemic toxicity and severe side effects. Out of 50% patients administrated to chemotherapy, only 5% survive. For these reasons, the identification of new drug designs and therapeutic strategies that could target cancer cells while leaving normal cells unaffected still continues to be a challenge. Despite advances that have led to the development of new therapies, treatment options are still limited for many types of cancers. This review provides an overview of platinum, copper and ruthenium metal based anticancer drugs in clinical trials and in vitro/in vivo studies. Presumably, copper and ruthenium complexes have greater potential than Pt(II) complexes, showing reduced toxicity, a new mechanism of action, a different spectrum of activity and the possibility of non-cross-resistance. We focus the discussion towards past, present and future aspects.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje